These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25957320)

  • 1. Neonatal screening for hereditary tyrosinaemia: are we there yet?
    Hadžić N; Vara R
    Arch Dis Child; 2015 Aug; 100(8):720-1. PubMed ID: 25957320
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcome of children with hereditary tyrosinaemia following newborn screening.
    McKiernan PJ; Preece MA; Chakrapani A
    Arch Dis Child; 2015 Aug; 100(8):738-41. PubMed ID: 25564536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 4. Deranged Liver Function in a Neonate.
    Peake RW
    Clin Chem; 2016 Nov; 62(11):1539-1541. PubMed ID: 27794060
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
    Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
    Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New drugs; nitisinone].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Nov; 150(46):2541-2. PubMed ID: 17152330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S; Baumann U
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
    De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
    Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
    [No Abstract]   [Full Text] [Related]  

  • 9. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
    Gissen P; Preece MA; Willshaw HA; McKiernan PJ
    J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
    Minoura H; Iwai M; Taniuchi Y; Katashima M; Takahashi H
    Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):342-8. PubMed ID: 26657126
    [No Abstract]   [Full Text] [Related]  

  • 11. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R; Sprietsma L; Rudnick DA
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug to treat rare pediatric liver disease.
    FDA Consum; 2002; 36(2):5. PubMed ID: 11989476
    [No Abstract]   [Full Text] [Related]  

  • 13. Recommendations for the management of tyrosinaemia type 1.
    de Laet C; Dionisi-Vici C; Leonard JV; McKiernan P; Mitchell G; Monti L; de Baulny HO; Pintos-Morell G; Spiekerkötter U
    Orphanet J Rare Dis; 2013 Jan; 8():8. PubMed ID: 23311542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
    Kurihara K; Toyoda H; Amoano K; Inoue M; Uchida K; Sakurai H; Hayashi A; Hirayama M
    Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN; Venugopalan P
    Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
    McKiernan PJ
    Drugs; 2006; 66(6):743-50. PubMed ID: 16706549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
    Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
    Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Weed Killer to Wonder Drug.
    Lock EA
    Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
    Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
    Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.